

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Olsen et al.

Docket No.: PF108P2D1

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: Concurrently Herewith

Examiner: Not Yet Assigned

For: Stanniocalcin Polynucleotides, Polypeptides, and
Methods Based Thereon

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references A-AH listed on the attached Form PTO/SB/08.

Copies of references A-AH were submitted by Applicants or cited by the Examiner in connection with United States Patent Application No. 09/840,989, filed on April 25, 2001, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application No. 09/840,989 for copies of references A-AH.


The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: July 9, 2003



Melissa J. Pytel

Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 610-5764

KKH/MJP/ba

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/840,989
				Filing Date	April 25, 2001
				First Named Inventor	Henrik S. Olsen
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	1	of	2	Attorney Docket Number	PF108P2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A	5,447,841	09-05-1995	Gray et al.	
	B	5,491,224	02-13-1996	Bittner et al.	
	C	5,538,869	07-23-1996	Siciliano et al.	
	D	5,545,524	08-13-1996	Trent et al.	
	E	5,837,498	11-17-1998	Olsen et al.	
	F	5,994,301	11-30-1999	Olsen et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	G	WO 88/03949 (PCT)	06-02-1988	Howard Florey Institute of Experimental Physiology and Medicine		
	H	WO 95/24411 (PCT)	09-14-1995	Human Genome Sciences, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	I	BUTKUS et al. "Purification and cloning of a corpuscles of stannius protein from Anguilla australis", Mol. & Cell. Endocrin. 54:123-133 (1987)	
	J	HADDAD et al. "Immunocytochemical localization of stanniocalcin cells in the rat kidney" Endocrinol. 137(5): 2113-2117 (1996)	
	K	LA FEBER et al. "Identification of hypocalcin (teleocalcin) isolated from trout stannius corpuscles", Gen. & Comparative Endocrin. 69:19-30 (1988)	
	L	MILLIKEN et al. "Effects of synthetic peptide fragments of teleocalcin (hypocalcin) on calcium uptake in juvenile rainbow trout (Salmo gairdneri)" Gen. & Comparative Endocrin. 77:416-422 (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/840,989
				Filing Date	April 25, 2001
				First Named Inventor	Henrik S. Olsen
				Art Unit	1647
				Examiner Name	C. Saoud
Sheet	2	of	2	Attorney Docket Number	PF108P2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	M	OLSEN et al. "Human stanniocalcin: a possible hormonal regulator of mineral metabolism" PNAS USA 93:1792-1796 (1996)	
	N	STERN et al. "Salmon stanniocalcin and bovine parathyroid hormone have dissimilar actions on mammalian bone", J. Bone & Mineral Res. 6(11):1153-1159 (1991)	
	O	WAGNER et al. "Human stanniocalcin inhibits renal phosphate excretion in the rat", J. Bone & Mineral Res. 12(2):165-171 (1997)	
	P	WAGNER et al. "Molecular cloning and cDNA sequence analysis of coho salmon stanniocalcin", Mol. & Cell. Endocrin. 90(1):7-15 (1992/1993)	
	Q	WAGNER et al. "Studies on the regulation and characterization of plasma stanniocalcin in rainbow trout", Mol. & Cell. Endocrin. 79:129-138 (1991)	
	R	CHANG et al. "A novel human cDNA highly homologous to the fish hormone stanniocalcin", Mol Cell Endocrinol. 112(2):241-7 (1995)	
	S	MADSEN et al. "Stanniocalcin: a novel protein regulating calcium and phosphate transport across mammalian intestine", Am J Physiol. 274(1 Pt 1):G96-102 (1998)	
	T	ZHANG et al. "Stanniocalcin: a molecular guard of neurons during cerebral ischemia", Proc Natl Acad Sci U S A. 97(7):3637-42 (2000)	
	U	ZHANG et al. "High expression of stanniocalcin in differentiated brain neurons", Am J Pathol. 153(2):439-45 (1998)	
	V	ZHANG et al. "Expression, purification, and bioassay of human stanniocalcin from baculovirus-infected insect cells and recombinant CHO cells", Protein Expr Purif. 12(3):390-8 (1998)	
	W	BIKFALVI et al. "Biological Roles of Fibroblast Growth Factor-2", Endocrine Reviews 18(1):26-45 (1997)	
	X	APFEL "Neurotrophic Factor Therapy-Prospects and Problems", Clin. Chem. Lab. Med. 39(4):351-355 (2001)	
	Y	GOLDSBY et al. "Kuby: Immunology", Cytokines 12:303-327 (2002)	
	Z	KANDEL et al. "Principles of Neural Science", Neurotransmitters 15:280-297 (2002)	
	AA	BORK et al. Trends in Genetics 12:425-427 (1996)	
	AB	BRENNER Trends in Genetics 15:132-133 (1999)	
	AC	SMITH et al. Nature Biotechnology 15:1222-1223	
	AD	DOERKS et al. Trends in Genetics 14:248-250 (1998)	
	AE	SKOLNICK et al. Trends in Biotech. 18(1):34-39 (2000)	
	AF	BORK Genome Res. 10:398-400 (2000)	
	AG	NGO et al. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495 (1992)	
	AH	WELLS Biochem. 29:8509-8517 (1990)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--